Karen M Rothacker1,2, Sam Armstrong3,4, Grant J Smith4, Nat Benjanuvatra5, Brendan Lay5, Peter Adolfsson6,7, Timothy W Jones3,4,8, Paul A Fournier5, Elizabeth A Davis3,4,8. 1. Department of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Western Australia, Australia. karen.rothacker@health.wa.gov.au. 2. The Centre for Child Health Research, Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia. karen.rothacker@health.wa.gov.au. 3. Department of Endocrinology and Diabetes, Perth Children's Hospital, Nedlands, Western Australia, Australia. 4. The Centre for Child Health Research, Telethon Kids Institute, The University of Western Australia, Subiaco, Western Australia, Australia. 5. School of Human Sciences, Division of Sport Science, Exercise and Health, The University of Western Australia, Crawley, Western Australia, Australia. 6. Department of Pediatrics, The Hospital of Halland, Kungsbacka, Sweden. 7. Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 8. School of Paediatrics and Child Health, The University of Western Australia, Crawley, Western Australia, Australia.
Abstract
AIMS/HYPOTHESIS: In individuals with type 1 diabetes, chronic hyperglycaemia impairs aerobic fitness. However, the effect of acute marked hyperglycaemia on aerobic fitness is unclear, and the impact of insulin level has not been examined. In this study, we explored if acute hyperglycaemia with higher or low insulin levels affects [Formula: see text] and other exercise performance indicators in individuals with type 1 diabetes. METHODS: Eligible participants were aged 14 to 30 years, with complication-free, type 1 diabetes and HbA1c ≤ 75 mmol/mol (≤9%). Participants exercised in a clinical laboratory under three clamp (constant insulin, variable glucose infusion) conditions: euglycaemia (5 mmol/l) with 20 mU [m2 BSA]-1 min-1 insulin (where BSA is body surface area) (Eu20); hyperglycaemia (17 mmol/l) with 20 mU [m2 BSA]-1 min-1 insulin (Hyper20); and hyperglycaemia (17 mmol/l) with 5 mU [m2 BSA]-1 min-1 insulin (Hyper5) on separate days. Participants and the single testing assessor were blinded to condition, with participants allocated to randomised testing condition sequences as they were consecutively recruited. Standardised testing (in order) conducted on each of the three study days included: triplicate 6 second sprint cycling, grip strength, single leg static balance, vertical jump and modified Star Excursion Balance Test, ten simple and choice reaction times and one cycle ergometer [Formula: see text] test. The difference between conditions in the aforementioned testing measures was analysed, with the primary outcome being the difference in [Formula: see text]. RESULTS: Twelve recreationally active individuals with type 1 diabetes (8 male, mean ± SD 17.9 ± 3.9 years, HbA1c 61 ± 11 mmol/mol [7.7 ± 1.0%], 7 ± 3 h exercise/week) were analysed. Compared with Eu20, [Formula: see text] was lower in Hyper20 (difference 0.17 l/min [95% CI 0.31, 0.04; p = 0.02] 6.6% of mean Eu20 level), but Hyper5 was not different (p = 0.39). Compared with Eu20, sprint cycling peak power was not different in Hyper20 (p = 0.20), but was higher in Hyper5 (64 W [95% CI 13, 115; p = 0.02] 13.1%). Hyper20 reaction times were not different (simple: p = 0.12) but Hyper5 reaction times were slower (simple: 11 milliseconds [95% CI 1, 22; p = 0.04] 4.7%) than Eu20. No differences between Eu20 and either hyperglycaemic condition were observed for the other testing measures (p > 0.05). CONCLUSIONS/ INTERPRETATION: Acute marked hyperglycaemia in the higher but not low insulin state impaired [Formula: see text] but to a small extent. Acute hyperglycaemia had an insulin-dependent effect on sprint cycling absolute power output and reaction time but with differing directionality (positive for sprint cycling and negative for reaction time) and no effect on the other indicators of exercise performance examined. We find that acute hyperglycaemia is not consistently adverse and does not impair overall exercise performance to an extent clinically relevant for recreationally active individuals with type 1 diabetes. FUNDING: This research was funded by Diabetes Research Western Australia and Australasian Paediatric Endocrine Group grants.
AIMS/HYPOTHESIS: In individuals with type 1 diabetes, chronic hyperglycaemia impairs aerobic fitness. However, the effect of acute marked hyperglycaemia on aerobic fitness is unclear, and the impact of insulin level has not been examined. In this study, we explored if acute hyperglycaemia with higher or low insulin levels affects [Formula: see text] and other exercise performance indicators in individuals with type 1 diabetes. METHODS: Eligible participants were aged 14 to 30 years, with complication-free, type 1 diabetes and HbA1c ≤ 75 mmol/mol (≤9%). Participants exercised in a clinical laboratory under three clamp (constant insulin, variable glucose infusion) conditions: euglycaemia (5 mmol/l) with 20 mU [m2 BSA]-1 min-1 insulin (where BSA is body surface area) (Eu20); hyperglycaemia (17 mmol/l) with 20 mU [m2 BSA]-1 min-1 insulin (Hyper20); and hyperglycaemia (17 mmol/l) with 5 mU [m2 BSA]-1 min-1 insulin (Hyper5) on separate days. Participants and the single testing assessor were blinded to condition, with participants allocated to randomised testing condition sequences as they were consecutively recruited. Standardised testing (in order) conducted on each of the three study days included: triplicate 6 second sprint cycling, grip strength, single leg static balance, vertical jump and modified Star Excursion Balance Test, ten simple and choice reaction times and one cycle ergometer [Formula: see text] test. The difference between conditions in the aforementioned testing measures was analysed, with the primary outcome being the difference in [Formula: see text]. RESULTS: Twelve recreationally active individuals with type 1 diabetes (8 male, mean ± SD 17.9 ± 3.9 years, HbA1c 61 ± 11 mmol/mol [7.7 ± 1.0%], 7 ± 3 h exercise/week) were analysed. Compared with Eu20, [Formula: see text] was lower in Hyper20 (difference 0.17 l/min [95% CI 0.31, 0.04; p = 0.02] 6.6% of mean Eu20 level), but Hyper5 was not different (p = 0.39). Compared with Eu20, sprint cycling peak power was not different in Hyper20 (p = 0.20), but was higher in Hyper5 (64 W [95% CI 13, 115; p = 0.02] 13.1%). Hyper20 reaction times were not different (simple: p = 0.12) but Hyper5 reaction times were slower (simple: 11 milliseconds [95% CI 1, 22; p = 0.04] 4.7%) than Eu20. No differences between Eu20 and either hyperglycaemic condition were observed for the other testing measures (p > 0.05). CONCLUSIONS/ INTERPRETATION: Acute marked hyperglycaemia in the higher but not low insulin state impaired [Formula: see text] but to a small extent. Acute hyperglycaemia had an insulin-dependent effect on sprint cycling absolute power output and reaction time but with differing directionality (positive for sprint cycling and negative for reaction time) and no effect on the other indicators of exercise performance examined. We find that acute hyperglycaemia is not consistently adverse and does not impair overall exercise performance to an extent clinically relevant for recreationally active individuals with type 1 diabetes. FUNDING: This research was funded by Diabetes Research Western Australia and Australasian Paediatric Endocrine Group grants.
Authors: Peter Adolfsson; Michael C Riddell; Craig E Taplin; Elizabeth A Davis; Paul A Fournier; Francesca Annan; Andrea E Scaramuzza; Dhruvi Hasnani; Sabine E Hofer Journal: Pediatr Diabetes Date: 2018-10 Impact factor: 4.866
Authors: A J Fahey; N Paramalingam; R J Davey; E A Davis; T W Jones; P A Fournier Journal: J Clin Endocrinol Metab Date: 2012-09-07 Impact factor: 5.958
Authors: Thanh Nguyen; Joyce Obeid; Rachel G Walker; Matthew P Krause; Thomas J Hawke; Karen McAssey; John Vandermeulen; Brian W Timmons Journal: Pediatr Diabetes Date: 2014-01-20 Impact factor: 4.866
Authors: Michael C Riddell; Ian W Gallen; Carmel E Smart; Craig E Taplin; Peter Adolfsson; Alistair N Lumb; Aaron Kowalski; Remi Rabasa-Lhoret; Rory J McCrimmon; Carin Hume; Francesca Annan; Paul A Fournier; Claudia Graham; Bruce Bode; Pietro Galassetti; Timothy W Jones; Iñigo San Millán; Tim Heise; Anne L Peters; Andreas Petz; Lori M Laffel Journal: Lancet Diabetes Endocrinol Date: 2017-01-24 Impact factor: 32.069
Authors: Neil E Hill; Christopher Campbell; Paul Buchanan; Midge Knight; Ian F Godsland; Nick S Oliver Journal: J Diabetes Sci Technol Date: 2016-09-30
Authors: C Purdon; M Brousson; S L Nyveen; P D Miles; J B Halter; M Vranic; E B Marliss Journal: J Clin Endocrinol Metab Date: 1993-03 Impact factor: 5.958
Authors: O Fricke; O Seewi; O Semler; B Tutlewski; A Stabrey; E Schoenau Journal: J Musculoskelet Neuronal Interact Date: 2008 Apr-Jun Impact factor: 2.041
Authors: Othmar Moser; Michael C Riddell; Max L Eckstein; Peter Adolfsson; Rémi Rabasa-Lhoret; Louisa van den Boom; Pieter Gillard; Kirsten Nørgaard; Nick S Oliver; Dessi P Zaharieva; Tadej Battelino; Carine de Beaufort; Richard M Bergenstal; Bruce Buckingham; Eda Cengiz; Asma Deeb; Tim Heise; Simon Heller; Aaron J Kowalski; Lalantha Leelarathna; Chantal Mathieu; Christoph Stettler; Martin Tauschmann; Hood Thabit; Emma G Wilmot; Harald Sourij; Carmel E Smart; Peter G Jacobs; Richard M Bracken; Julia K Mader Journal: Diabetologia Date: 2020-12 Impact factor: 10.122